Rexahn Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
August 07, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Reports Second Quarter 2018 Financial Results
August 06, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018
June 14, 2018 10:00 ET
|
Rexahn Pharmaceuticals
Three of four proposals pass with shareholder approval Annual Meeting adjourned solely with respect to Proposal 3 – approval of an amendment to the Company’s Amended and Restated Certificate of...
Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
June 04, 2018 08:00 ET
|
Rexahn Pharmaceuticals
Phase 2a Trial of RX-5902 Advances to Stage 2 Based on Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Heavily Pre-treated Metastatic Triple Negative Breast Cancer...
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
May 15, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Reports First Quarter 2018 Financial Results
May 07, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., May 07, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2018 08:00 ET
|
Rexahn Pharmaceuticals
Preliminary Safety and Efficacy Data from Phase 1b/2a Trial of RX-5902 in Advanced Triple Negative Breast Cancer Updated Safety and Efficacy Data on RX-3117 in Advanced Urothelial (Bladder) Cancer ...
Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
March 13, 2018 08:00 ET
|
Rexahn Pharmaceuticals
B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on March 16Oppenheimer 28th Annual Healthcare Conference on March 21 ROCKVILLE, Md., March 13, 2018 (GLOBE...
Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results
March 12, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., March 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
February 12, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...